Accessibility
Animation
Accessibility

Connect with Labcorp at the American Association for Cancer Research (AACR) Annual Meeting 2024

April 5-10, 2024 | San Diego, CA | Booth 1041

Unleash the power of precision medicine at AACR 2024.

Accelerate your companion diagnostic and precision medicine programs with comprehensive testing solutions. Development of precision oncology therapeutics is complex. Labcorp has the unique ability to support you from preclinical discovery through diagnostic commercialization. We leverage our rich experience to empower you to make informed decisions at each stage.

Join us at booth 1041 to discover more about our extensive portfolio.

  • Labcorp® Plasma Detect™: A tumor-informed whole genome ctDNA MRD assay. Accelerate oncology therapeutic development with fast, high confidence MRD assessment for global clinical trials.
  • Drug discovery: In vitro and in vivo pharmacology efficacy models, in vivo imaging technologies, in vitro assessments and focal radiation capabilities
  • Clinical development and commercialization: Biomarker discovery and strategy development, companion diagnostic development, sponsored testing and NGS kitted solutions
  • Testing solutions: Streamlined CGP solutions; centralized services for hereditary, tissue, liquid and heme testing; translational research opportunities for kitted solutions and centralized services
     
Schedule a meeting

Spotlight Theater

          Date: Tuesday, April 9, 2024

          Time: 10:00 a.m.​

          Location: Spotlight Theater A​

Title: Biomarker solutions for all: Innovative solid tumor MRD detection and immune profiling solutions for advanced drug development​

Speakers: 

  • Taylor Jensen, PhD, VP, Oncology R&D Science, Labcorp
  • Mark Sausen, PhD, Executive Director, Translational Development, Labcorp
  • Sarabjot Pabla, PhD, Head of Clinical and Research Bioinformatics, Labcorp
  • Remond Fijneman, PhD, Principal Investigator and Associate Group Leader, Translational Gastrointestinal Oncology Group, Netherlands Cancer Institute

Oral Presentation

          Date: Tuesday, April 9, 2024

          Time: 3:10 PM - 3:25 PM

          Location: Ballroom 6 CF - Upper Level - Convention Center

Title: Clinical validity of post-surgery circulating tumor DNA testing in stage III colon cancer patients treated with adjuvant chemotherapy: The PROVENC3 study ​

Speakers: Carmen Rubio Alarcon, PhD, Netherlands Cancer Institute, Amsterdam


Download posters:

Session Date & TimePresenting AuthorTitleDetails
Sunday, April 7
Sunday, April 7
1:30-5:00 PM
David Draper, Yewei Xing and Scott WiseNK cell ADCC assays: Leveraging flow cytometry and reporter cell lines for enhanced biological relevance and throughputTrack: Immunology 
Session: Biomarkers, Immune Monitoring and Immune Assays 
Abstract #83 
Section: 3
Sunday, April 7
1:30-5:00 PM
Hardik ParikhLandscape of HIF-1α expression across 24,186 solid tumors using comprehensive immune profilingTrack: Molecular/Cellular Biology and Genetics 
Session: Cellular Stress Responses 1  Abstract #379 
Section: 16
Sunday, April 7
1:30-5:00 PM
Maria Fatteh (external)Liquid biopsy-informed precision oncology clinical trial to evaluate the utility of ctDNA comprehensive genomic profilingTrack: Clinical Research 
Session: Circulating Nucleic Acids 1 
Abstract #970 
Section: 40


 

Session Date & TimePresenting AuthorTitleDetails
Monday, April 8
Monday, April 8
9:00 AM - 12:30 PM
Ingrid A. Franken(external)Molecular characterization of stage III colon cancer patients with recurrence after adjuvant chemotherapyTrack: Clinical Research 
Session: Predictive Biomarkers 1 Abstract #2496
Section: 43
Monday, April 8
1:30-5:00 PM
Caitlin Schroyer and Shanshan ZhouSpatial transcriptomic study of the tumor microenvironment in HNSCCTrack: Clinical Research 
Session: Biomarkers in Clinical Trials 
Abstract #3652
Section: 40
Monday, April 8
1:30-5:00 PM
Li Shen (external)Prevalence of claudin18.2 expression in gastric/gastroesophageal junction adenocarcinoma among patients in TranStar101 and TranStar102 clinical trialsTrack: Clinical Research 
Session: Biomarkers in Clinical Trials 
 


 

Session Date & TimePresenting AuthorTitleDetails
Tuesday, April 9
Tuesday, April 9
9:00 AM - 12:30 PM
Grant HoggValidation of an Automated, Scalable Comprehensive Genomic Profiling Assay for Hematologic Malignancies Track: Experimental and Molecular Therapeutics 
Session: Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes 
Abstract #4628
Section: 26
Tuesday, April 9
9:00 AM - 12:30 PM
Robert SummersgillPre-analytical characterization of cell-free DNA to enable liquid biopsy for solid tumors Track: Clinical Research 
Session: Circulating Nucleic Acids 4 
Abstract #5020
Section: 40
Tuesday, April 9
9:00 AM -12:30 PM
I.A. Franken (external)MEDOCC-CrEATE trial: Feasibility of measuring circulating tumor DNA after surgery to guide adjuvant chemotherapy in stage II colon cancer patients Track: Clinical Research 
Session: Circulating Nucleic Acids 4 
Abstract #5022
Section: 40
Tuesday, April 9
9:00 AM - 12:30 PM
Amanda HarveyAnalytical Performance of Contrived Samples for Validation of Liquid Biopsy Assays Track: Clinical Research 
Session: Circulating Nucleic Acids 4 
Abstract #5017
Section: 40
Tuesday, April 9
9:00 AM - 12:30 PM
Kerry-Ann BrightSubcutaneous vs. Orthotopic Tumor models: A Comparative Assessment Track: Tumor Biology 
Session: Models to Study Immune Cells in the Tumor Microenvironment 
Abstract #4204
Section: 10
Tuesday, April 9
9:00 AM - 12:30 PM
Justin SniderAnalysis of tumor heterogeneity in syngeneic models; CT26.WT colon carcinoma and 4T1-Luc2-1A4 breast carcinoma in female BALB/cAnNHsd mice Track: Tumor Biology 
Session: Tumor Evolution Models and Technologies 
Abstract #4305
Section: 13
Tuesday, April 9
9:00 AM - 12:30 PM
David DraperInvestigating CAR-T cell efficacy and activation in the disseminated NALM6-luc human B-cell acute lymphoblastic leukemia model Track: Immunology 
Session: Adoptive Cell Therapies 3: CAR-T Cells 
Abstract #4002
Section: 2
Tuesday, April 9 
1:30-5:00 PM
Jennifer B. JacksonEnhanced detection of ctDNA molecular response for immunotherapy treated non-small cell lung cancer through analyses of cell-free and matched white blood cell DNATrack: Clinical Research 
Session: Predictive Biomarkers 6
Abstract #6443
Section: 44
Tuesday, April 9
1:30-5:00 PM
J. Lim (external collaboration)Metabolic reprogramming enhances expansion and potency of CAR T cells (Xcelbio collaboration) Track: Clinical Research 
Session: Adoptive Cellular Therapy 2
Abstract #6334
Section: 40
Tuesday, April 9
1:30 PM - 5:00 PM
Sheri BarnesDigital spatial profiling of MC38 colon carcinoma following checkpoint inhibition Track: Tumor Biology 
Session: Spatial Resolution of the Tumor Microenvironment Abstract #5493
Section: 10
Tuesday, April 9
1:30 PM - 5:00 PM
Yewei XingGeneration of new oncology cell models through long-term acclimation under hypoxic and hyperbaric culture conditions Track: Experimental and Molecular Therapeutics 
Session: Novel Therapeutics and Preclinical Models Abstract #6005
Section: 28
Tuesday, April 9,
1:30-5:00 PM
Obada Ababneh*(external)The predictive role of TNF-related genes in patients receiving immune checkpoint inhibitors Track: Clinical Research Excluding Trials 
Session: Predictive Biomarkers 5 Abstract #6393
Section: 43
Tuesday April 9,
1:30 PM - 5:00 PM
P.H.A. Wisse (external)Comparison of FIT and ctDNA tests for detection of individuals with colorectal cancer in population based screening Track: Prevention / Early Detection / Interception,Population Sciences 
Session: Biomarker Based Screening Abstract #6079
Section: 31
Tuesday Apr 9, 
3:10 PM - 3:25 PM 
Ballroom 6 CF - Upper Level - Convention Center
Carmen Rubio-Alarcón (external)Clinical validity of post-surgery circulating tumor DNA testing in stage III colon cancer patients treated with adjuvant chemotherapy: the PROVENC3 study Track: Clinical Research
Session: Liquid Biopsy 
ORAL PRESENTATION


 

Session Date & TimePresenting AuthorTitleDetails
Wednesday, April 10
Wednesday, April 10
9:00 AM - 12:30 PM
Sarabjot PablaLandscape of TIGIT and PD-L1 co-expression in solid tumors Track: Clinical Research 
Session: Immune Checkpoint Inhibitor Therapy 
Abstract #7526 
Section: 42


 

Register for AACR 2024